Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations.. Drugs (Pharmaceuticals), Aduhelm (Drug), Alzheimer's Disease, Medicare, Biogen Inc, Cleveland Clinic, Blue Cross and Blue Shield Assn, Food and Drug Administration, Mount Sinai Medical Center, Veterans Affairs Department, Vounatsos, Michel